å»çå¾äºè ããããããã¼ãã¦ã¤ã«ã¹ï¼HPVï¼äºé²æ¥ç¨®ã®æºåãããæ§åï¼2016å¹´5æ17æ¥æ®å½±ãè³æåçï¼ã(c)ORLANDO SIERRA / AFP ã11æ4æ¥ AFPããããããã¼ãã¦ã¤ã«ã¹ï¼HPVï¼ã®ææãé²ãã¯ã¯ãã³ãæ¥ç¨®ããè±å½äººå¥³æ§ã®éã§ãåå®®é ¸ï¼ããï¼ããã®çºç件æ°ãæ¿æ¸ããã¨ã®ç 究çµæããè±å»å¦èªãã©ã³ã»ããï¼The Lancetï¼ãã«æ²è¼ãããã ç 究ã§ã¯ã2008å¹´ã«è±ã¤ã³ã°ã©ã³ãã§HPVäºé²æ¥ç¨®ããã°ã©ã ãå°å ¥ãããåå¾ã§ãåå®®é ¸ããã¨åããç¶æ ã®çºççãæ¯è¼ãããããã¨ãããã°ã©ã å°å ¥å¾ã«ãå¤§å¹ ãªæ¸å°ããè¦ãããç¹ã«å¯¾è±¡å¹´é½¢ã«ãªã£ã¦ããã«æ¥ç¨®ãåãã女æ§ã§èããæ¸å°ãã¦ãããã¨ãåãã£ãã è«æã¯ãã2価ã¯ã¯ãã³ããµã¼ããªãã¯ã¹ï¼Cervarixï¼ããç¨ããHPVã¯ã¯ãã³æ¥ç¨®ã®å¹æã示ãåã®ç´æ¥ç証æ ãã ã¨è¿°ã¹ã¦ããã ãªã¹ã¯ã®æ¸å°ã¯å¯¾è±¡å¹´é½¢ã«ãªã£ã¦ããã®12
ç±³ã«ãªãã©ã«ãã¢å·ããµããã§ãæ¿åºã«ããã¯ã¯ãã³ç¾©ååã«æè°ããèªç©ºå®å®å±ï¼NASAï¼è·å¡ï¼2021å¹´11æ1æ¥æ®å½±ï¼ã(c)Robyn Beck / AFP ã11æ5æ¥ AFPãç±³æ¿åºã¯4æ¥ãå½å ã®å´åè æ°åä¸äººã«æ°åã³ããã¦ã¤ã«ã¹ã¯ã¯ãã³ã®æ¥ç¨®ãä¿ããã¨ãç®çã¨ããå³æ ¼ãªè¦åããæ¥å¹´1æ4æ¥ã«æ½è¡ããã¨çºè¡¨ããã å¾æ¥å¡100人以ä¸ã®ä¼æ¥ã§ã¯ãåæ¥ã¾ã§ã«ã¯ã¯ãã³æ¥ç¨®ãæ¸ã¾ããªãã£ãå¾æ¥å¡ã«ã¯æä½é±1åã®æ¤æ»ã義ååããããå»çå¾äºè ã¨é£é¦æ¿åºã®è«è² æ¥è ã¯ãæ¥ç¨®ãå®å ¨ã«ç¾©åä»ããããã対象ã¯å½å å´åè ã®3åã®2以ä¸ã«ä¸ãã ç±³å½ã§ã¯ãã§ã«ä¸é¨ã®å¤§ä¼æ¥ãå·ãã¯ã¯ãã³ç¾©ååã«è¸ã¿åã£ã¦ããããä»åã®æªç½®ã¯ããã¾ã§ç±³æ¿åºãæã¡åºããä¸ã§æãå³æ ¼ãªã³ãã対çã¨ãªãã ç±³å½ã§ã¯ããæ°ãæãå¤ç°æ ªããã«ã¿æ ªãã®å½±é¿ã§çµæ¸ã®å復ãã¼ã¹ãéåãå½å ã®ã¯ã¯ãã³æ¥ç¨®çã伸ã³æ©ãä¸ãã¸ã§ã¼ã»ãã¤ãã³ï¼Joe
ç½å®³ãèµ·ããéã®é¿é£æéå¶ãå¹çåããé¡èªè¨¼ã·ã¹ãã ã®å®è¨¼å®é¨ãããã¾ããã NTTãã³ã¢ãéçºããAIã使ã£ãé¡èªè¨¼ã·ã¹ãã ã¯ãäºåã«é¡ã®ç»åãã¼ã¿ã¨å人æ å ±ãç»é²ãã¦ãããã¨ã§ãç¬æã«é¿é£æã®åãä»ããæ¸ã¾ãããã¨ãã§ãã¾ãã å»å¹´ã®çæ¬è±ªé¨ã§è¢«ç½ããå «ä»£å¸ã§ã¯ãè·å¡ãå¤ãã®é¿é£è ã®ææ¡ã«è¿½ããããªã©èª²é¡ãåºã¾ããããã®ã·ã¹ãã ã§ã¯ãé ãé¢ãã¦ãã¦ãé¿é£ç¶æ³ããªã¢ã«ã¿ã¤ã ã§å ±æã§ããã»ããæ¥è§¦ããã«ä½æ¸©æ¸¬å®ãããã¨ãå¯è½ã§æ°åã³ãã対çã¨ãã¦ãæå¾ ããã¦ãã¾ãã å «ä»£å¸ã¨ï¼®ï¼´ï¼´ãã³ã¢ã¯é¿é£æã§ã®ã·ã¹ãã å°å ¥ã«åãã¦ä»å¾ãæ¤è¨ãé²ãã¦ããã¨è©±ãã¦ãã¾ãã
ãæ°åã³ããã¯ã¯ãã³æ¥ç¨®å¾ã«ãããã¾ãã«ãå¿ççã»å¿èçãçºçããäºä¾ãå ±åããã¦ãã¾ãã 10æ15æ¥ãåå´çãæ¥ãããã¼ã ãã¼ã¸ä¸ã§ãããªæ³¨æåèµ·ãå§ãããããã«ããã¨ãã10代ã»20代ã®ç·æ§ã§ã¯ãæ¦ç°ï¼ã¢ãã«ã社ã®ã¯ã¯ãã³ããããã¡ã¤ã¶ã¼ç¤¾ã®ã¯ã¯ãã³ã®æ¹ããå¿ççã»å¿èçãçãããå ±åã®é »åº¦ãä½ãå¾åãã¿ããããããã¡ã¤ã¶ã¼ç¤¾ã®ã¯ã¯ãã³ãå¸æããå ´åã¯ãäºç´ãåãç´ãã°ãã¡ã¤ã¶ã¼ç¤¾ã®ã¯ã¯ãã³ãåãããããã¨ãã¦ããã ã¯ã¯ãã³æ¥ç¨®ã®å¯åå¿ã¨ãã¦å¿ççãçºçãããªã¹ã¯ããããã¨ã¯ãå½åããå½å å¤ã§ææããã¦ãããåå´çã10æ22æ¥ã«å ¬è¡¨ãããå»çæ©é¢ããã®å¯åå¿çãå ±åç¶æ³ãã«ããã¨ãï¼æ17æ¥ããå§ã¾ã£ããã¡ã¤ã¶ã¼ã®ã¯ã¯ãã³æ¥ç¨®å¾ã«å¿ççãçºçããä¾ã¯72件ã§ãï¼æ22æ¥ããå§ã¾ã£ãã¢ãã«ãã§ã¯65件ã¨ãªã£ã¦ãããåããã製é 販売æ¥è ããã®å¯åå¿çãå ±åç¶æ³ãã§ã¯ããã¡ã¤ã¶ã¼ã11
ä¼è¨æ¤æ»é¢ã¯5æ¥ãå½ã®2020年度決ç®ã®æ¤æ»å ±åã岸ç°æéé¦ç¸ã«æåºãããç¨éã®ç¡é§é£ãããè³ç£ãæå¹æ´»ç¨ã§ãã¦ããªãç¶æ³ãææããã®ã¯210件ã§ãç·é¡ç´2108ååã ã£ããæ°åã³ããã¦ã¤ã«ã¹å¯¾çäºæ¥ãå·¡ãæ¤æ»ã§ã¯ãç´22å åãæªå·è¡ã«ãªã£ã¦ãããæ¿åºã調éããå¸è£½ãã¹ã¯ã大éä¿ç®¡ããããªã©ãã¦ããå®æ ãå¤æããã210件ã®ææ件æ°ã¯1994年以éã§æå°ã§ãã³ããã®æææ¡å¤§ã«ãã£ã¦å®å°æ¤æ»ãå¶
åçå´åçã¯æ°åã³ããã¦ã¤ã«ã¹ã¯ã¯ãã³ãæ¥ç¨®ããªãå´åè ãæ±è·è ã«ä¸å©çãçããªãããä¼æ¥ã«å¯¾å¿ãä¿ããæ¥ç¨®ããªããã¨ã ããçç±ã¨ãã解éãéãæ¢ãã¯è¨±ãããªãã¨ããæ¥ç¨®ãæ¡ç¨æ¡ä»¶ã¨ããå ´åãçç±ãªã©ã®æ示ãå¼ã³ããããå¥åº·ä¸ã®çç±ãªã©ã§ã¯ã¯ãã³ãæ¥ç¨®ã§ããªã人ã«å·®å¥çãªæ±ããçããªãããé æ ®ãããé¦ç¸å®é¸ã«ããã¨1æ¥æç¹ã§2åæ¥ç¨®ãçµãã人ã¯å ¨äººå£ã®72.0%ãæ¿åºã¯å¸æãããã¹ã¦ã®äººã11
æ±ã¢ã¸ã¢ãä¸å¿ã«æ¥ä¸éãªã©15ã«å½ãåå ããå°åçãªå æ¬ççµæ¸é£æºï¼RCEPï¼åå®ãåãåºããæ¥æ¬æ¿åºã¯åå®çºå¹ã«ä¼´ãé¢ç¨æ¤å»ã»åæ¸ãªã©ã§é¨åãç´ æã®è¼¸åºãå¢ããæ¥æ¬ã®å½å ç·çç£ï¼GDPï¼ãç´2.7%æ¼ãä¸ããå¹æãããã¨è©¦ç®ãããçµæ¸å¹æã§ã¯ç±³å½ãæããç°å¤ªå¹³æ´çµæ¸é£æºåå®ï¼TPPï¼ãä¸åããTPPã¨æ¯ã¹ãã¨å½æä¼æ¥æ¹é©ãç°å¢ãå´ååé¡ã®è¦å®ãçãè¾¼ãã§ãããã«ã¼ã«ã®æ°´æºã¯ä½ãã ããæ¥æ¬ã«ã¨
10æ31æ¥ãèµ°è¡ä¸ã®äº¬çç·ã®è»å ã§ã24æ³ã®ç·ã70代ç·æ§ã®å³è¸ãåºããªã©17人ã®ä¹å®¢ã«ã±ã¬ããããä¸ãã©ã¤ã¿ã¼ãªã¤ã«ãæãã¦ç«ãä»ããã¨ããäºä»¶ããã£ãã 容çè ã¯è¦å¯ã«å¯¾ãã¦ãä»äºã«å¤±æãã¦ãå人é¢ä¿ããã¾ããããªãã£ãããªã©ã¨è¿°ã¹ã¦ããããã§ãããã¾ãç·ã2019å¹´ã«ä¸æ ãããæ ç»ãã¸ã§ã¼ã«ã¼ãã®ä¸»äººå ¬ã®ãããªæè£ ããã¦ãããã¨ã«ã¤ãã¦ã¯ãã¸ã§ã¼ã«ã¼ã«æ§ãã¦ãããã¨è¿°ã¹ã¦ããã ä»äºã®å¤±æãå人é¢ä¿ã¨ãã極ãã¦å人çãªçç±ã§ããããç¯è¡ã¨ãã¦ããä¹å®¢ããã¤ãã§åºãã¦é»è»ãçãããã¨ããå¹¼ç¨ã§æ®å¿ãªèãæ¹ãããããèªåã§ã¯æ»ããªãã®ã§æ»åã«ãªãããã£ããã¨ãè¨ã£ã¦ãããã¨ããã極ãã¦èº«åæãªç¯è¡ã§ããã¨ããæ¹å¤ãå¤ãã®ã¯å½ç¶ã ããã ä»äºã«å¤±æããï¼ å人é¢ä¿ããã¾ããããªãï¼ ãã®ç¨åº¦ã®ãã¨ã§ï¼ï¼ åãåæã ããã ãããã¯å¤ãã®äººãæã£ã¦ããã§ãããããã®ç¨åº¦ã®ãã¨ã§ããããªé ·ãäº
ããæ¶æ» ã®ç§è¨£ã¯ãå殺ããã«ããã¾ããã ã¢ã¡ãªã«ã®ããµãã¥ã¼ã»ããå·¥ç§å¤§å¦ï¼MITï¼ã§è¡ãããç 究ã«ããã°ããã¦ã¹ã®ä½ããåãåã£ããããç´°èã®DNAããºã¿ãºã¿ã«ãã¦ï¼å殺ãã«ãã¦ï¼ãåã³è «çã«æ»ããã¨ãããå ç«çæ³ã®æ²»çå¹æãå¤§å¹ ã«ä¸æããã¨ã®ãã¨ã æ°ãã«éçºããããå殺ããæ³ã¯ãé»è²è «ã¨ä¹³ããã«å¯¾ãã¦ãå¹æãçºæ®ããå ç«çæ³ã®ä½µç¨ã«ãã£ã¦ãã¦ã¹ã®40%ã«ããã¦è «çãå®å ¨ã«æ¶æ» ãã¾ããã ãããããã£ããã©ããã¦ä¸é¨ã®ç´°èããå殺ããã«ãã¦æ»ãã ãã§ãå ç«ã·ã¹ãã ã¯è «çå ¨ä½ãæ»æãå§ããã®ã§ããããï¼ ç 究å 容ã®è©³ç´°ã¯10æ19æ¥ã«ãScience Signalingãã«å ¬éããã¦ãã¾ãã Chemotherapy-Injured Tumor Cells Boost Anticancer Effectiveness of Immune Checkpoint Inhibition ht
ãã§ã¤ã¹ããã¯ãä»®æ³3次å 空éãã¡ã¿ãã¼ã¹ãæ§ç¯ã«èºèµ·ã ãç·é¡100åãã«ï¼1å åï¼ãæè³ããã¨ãã社åããã¡ã¿ï¼Metaï¼ãã¸ã¨å¤æ´ãæå§ãã¨ãã¦ãå社ã¯2021å¹´9æããã¼ãã£ã«ãªã¢ãªãã£ï¼VRï¼æ©å¨ãOqulus Quest2ãã®ãã¸ãã¹ä¼è°ç¨ã½ãããHorizon Workroomsããå ¬éããããã¼ãã£ã«ä¼è°å®¤ã«åå è ãå身ã®ã¢ãã¿ã¼ã¨ãã¦éãããã¼ãã£ã«ãªã³ãã¥ãã±ã¼ã·ã§ã³ãå³ãããã®ãã¼ã«ã ãã ãããã®ã½ããã®æç¨æ§ããå社ããã®å ã«è¦æ®ãããã¡ã¿ãã¼ã¹ãã®å°æ¥æ§ãããã£ã¦ã¯è³å¦ä¸¡è«ããã¾ãã¦ãããããã«ä¸ä»£ã®å¤§åã«ã¨ã£ã¦ã¯ããã§ã¤ã¹ããã¯ã®æã¡åºãä¸çã¯ãã¾ã ç°æ¬¡å ã®é ãä¸çã¨ãã£ãã¨ãããã§ã¯ãå°æ¥ã³ã¢ã¦ã¼ã¶ã¼ã«ãªãå¾ãè¥ãä¸ä»£ã«ã¯åãå ¥ããããã®ãã30ï½40代ã®ç·¨éé¨ã¹ã¿ããã ãã§ãªããZä¸ä»£ã®ä¾¡å¤è¦³ãä¼ãç¶ããAMF社é·ã®æ¤æ¨éä½³ããã«ãVRã¨Workroomsã«è§¦
ç±³Metaï¼æ§Facebookï¼ã¯11æ1æ¥ï¼ç¾å°æéï¼ãç®èã®ãããªè§¦è¦ã½ããã»ã³ãµã¼ãReSkinããçºè¡¨ãããè¨è¨ãåºæ¬ã¢ãã«ããªã¼ãã³ã½ã¼ã¹ã§å ¬éãããMetaã®AIç 究è ãã«ã¼ãã®ã¼ã¡ãã³å¤§å¦ã¨å ±åã§éçºãããå¾æ¥ã®ã»ã³ãµã¼ããä½ã³ã¹ãã§è£½é ã§ããå¹ åºãç¨éã§è§¦è¦ã¢ã¸ã¥ã¼ã«ã«å©ç¨ã§ããã¨ãã¦ããã ãã¼ã¯ã»ã¶ãã«ã¼ãã¼ã°CEOã¯Facebookã¸ã®æ稿ã§ãReSkinã§ãã¡ã¿ãã¼ã¹ã®ä»®æ³ãªãã¸ã§ã¯ãã¨ã®ç©ççç¸äºä½ç¨ã«ä¸æ©è¿ã¥ããã¨èªã£ããå°æ¥ReSkinã»ã³ãµã¼ãæ¡ç¨ããã°ãã¼ããã¯ããã°ãæ¶ç©ºã®ç©ä½ã«è§¦ã£ãæã«ããã®ç©ä½ã«ãµããããæ触ãå¾ãããããã«ãªããããããªãã ReSkinã®âç®èâã¯ãåã3mmæªæºã®ã´ã ç¶ãã©ã¹ããã¯ã«ç£æ§ç²åãã¡ãã°ãããã®ãä½ãã«ãµããã¨ãã©ã¹ããã¯ãå¤å½¢ããåãè¾¼ã¾ããç²åã«ãã£ã¦çæãããå°å ´ãå¤åããããã®å¤åããã¤ã¯ãããããè¨é²ãã¦
ã¡ã¿ãã¼ã¹ä¸è²ã¨ãªã£ãâæ§ãã§ã¤ã¹ããã¯âã«ããConnect 2021åºèª¿è¬æ¼ çºè¡¨ã¾ã¨ã ã¡ã¿ï¼æ§ãã§ã¤ã¹ããã¯ï¼ã¯ãæ¥æ¬æé2021å¹´10æ29æ¥åå2æããã年次ã®éçºè åãã¤ãã³ãConnect 2021ã®åºèª¿è¬æ¼ãè¡ãªãã¾ãããç´1æéåã®åºèª¿è¬æ¼ã§ã¯ãCEOã®ãã¼ã¯ã»ã¶ãã«ã¼ãã¼ã°æ°ããã¡ã¿ãã¼ã¹ãæ§æ³ãèªããã¨ã«å¤ãã®æéãå²ããã¦ãã¾ãã æ¬è¨äºã§ã¯ãConnect 2021ã®åºèª¿è¬æ¼ãæ¯ãè¿ããªãããå ¬å¼ããã°çã§æããã«ãªã£ã¦ããç¹ãã¾ã¨ãã¦ãä¼ããã¾ãã ã¡ã¿ãã¼ã¹æ§æ³ åºèª¿è¬æ¼ã®æå¾ã«ããOne More Thingãï¼æå¾ã«ããä¸ã¤â¦ï¼ã¨ãã§ã¤ã¹ããã¯ãããã¡ã¿ãã¸ã®ç¤¾åå¤æ´ãå ¬è¡¨ããããã«ãä»åã®åºèª¿è¬æ¼ã®ãã¼ã¯ã¼ãã¯ãã¡ã¿ãã¼ã¹ãã§ããããã®ã¤ã¡ã¼ã¸ãå ±æãããã¨ã«éããç½®ããã¾ããã ã¡ã¿ãã¼ã¹ãVRãARãªã©æ§ã ãªå½¢ã§ã¢ã¯ã»ã¹ãããã®ã«ãªããã¨ãçæ´»ã娯
ä¸çã§æ°åã³ããã¦ã¤ã«ã¹ã®ææã«ä¼´ãæ»è æ°ãç´¯è¨500ä¸äººãè¶ ãããå£ç¯æ§ã¤ã³ãã«ã¨ã³ã¶ãªã©ã¨æ¯ã¹ã¦ãªãæ»äº¡ãªã¹ã¯ã¯é«ããã®ã®ãå é²å½ãä¸å¿ã«ã¯ã¯ãã³å¹æã浸éããè´æ»çã¯ãã¼ã¯ã®3åã®1以ä¸ã«ä½ä¸ãããã¯ã¯ãã³ã®åå¨ã解æ¶ãã¦æ¥ç¨®ã®é ããéä¸å½ã¸ã®ä¾çµ¦ãä¿ãã¨åæã«ãéçºã®é²ãæ²»çè¬ã®æ®åãæ¥ããã³ããã®è´æ»çãä¸æ®µã¨å¼ãä¸ãããã¨ãæ¥å¸¸çæ´»ãåãæ»ãã«ã®ã¨ãªããç±³ã¸ã§ã³ãºã»ãããã³ã¹å¤§ã®é
æ¿åºã»ä¸å ã¯ï¼æ¥ãæ°åã³ããã¦ã¤ã«ã¹ã®æææ¡å¤§ãåããæ¯æ´çã¨ãã¦ãï¼ï¼æ³ä»¥ä¸ã®åã©ããè¥è ã«ç¾éï¼ï¼ä¸åãä¸å¾æ¯çµ¦ããæ¹éãåºãããæå¾å¶éã¯è¨ããªããæ¿åºãï¼ï¼æ¥ã«ãåãã¾ã¨ãã大åçµæ¸å¯¾çã«çãè¾¼ãããã¤ãã³ãã¼ã«ã¼ããä¿æããå ¨å½æ°ã対象ã«ãï¼äººï¼ä¸åç¸å½ã®ãã¤ã³ããä»ä¸ããæ¹åã§ã調æ´ãã¦ããã ç¾é給ä»ã®å¯¾è±¡ã¯ï¼æ³ããé«æ ¡ï¼å¹´çã¾ã§ã¨ããé«æ ¡ã«é²å¦ãã¦ããªãè¥è ãå«ããã対象ã¯ç´ï¼ï¼ï¼ï¼ä¸äººã«ã®ã¼ãè¦éãã§ãäºç®é¡ã¯ç´ï¼å åãè¦è¾¼ããå ¥åã»å ¥å¦ã·ã¼ãºã³ãè¿ããæ¥æ¥ã¾ã§ã«æ¯çµ¦ãå®ç¾ãããèãã ã å¿ è¦ãªè²¡æºã«ã¤ãã¦ã¯ãï¼ï¼ï¼ï¼å¹´åº¦ã®æ±ºç®å°ä½éç´ï¼å ï¼ï¼ï¼ï¼ååãå ã¦ããã¨ãªã©ãæ³å®ãã¦ãããç¾é給ä»ãå«ãçµæ¸å¯¾çã¯æ°åå åè¦æ¨¡ã¨ãªãè¦è¾¼ã¿ã§ãæ¿åºã»ä¸å ã¯çµæ¸å¯¾çã®å 容ãåæ ããï¼ï¼å¹´åº¦è£æ£äºç®æ¡ãå¹´å ã«æç«ããããèãã ã åã©ããã¸ã®ï¼ï¼ä¸å給ä»ãå·¡ã£ã¦ã¯ãå ¬æå ãè¡é¢é¸å ¬ç´ã§
ãã®ãããçå±ã¤ãããã¾ããã¾ããããªãã£ãããã§ãã ä»ã®å½ã¨éãæ¥æ¬ã«ã¯ããããçµæ¸çãªå³ããç°å¢ã«é¥ã£ã人ãæ¯æ´ããå¶åº¦ã¯å¤±æ¥ä¿éºãçæ´»ä¿è·ãçæ´»ç¦ç¥è³éå¶åº¦ãå¦çæ¯æ´ç·æ¥çµ¦ä»éãªã©ããããä»ã«ããã¾ãããã ã¤ã¾ãããç¹å¥å®é¡çµ¦ä»éãã¯ããããã®ç®çèªä½ãææ§ã ã£ããã§ããã ç¡çããçç±ãã¤ããã°æ°åã³ããã§ã¯ã»ã¨ãã©ã®æ¹ããªã«ãããã®çµæ¸è¢«å®³ãåãããããã®ç·æ¥æ¯æ´ã¨ãããã¨ã§ããã»ã»ã» ããã§æ¶è²»ãåãã°ããã¨ããçµæ¸å¯¾ççãªæå³ã大ããã£ãã¨ã¯æãã¾ãã æè¿æ¥æ¬ç¶æ°ãå ¬ç´ã«æ²ãã¦è©±é¡ã«ãªã£ã¦ãããã¼ã·ãã¯ã¤ã³ã«ã ã®å®é¨çãªæå³ã¨ãã¦ã¯è¯ãã£ãã®ããããã¾ãããã©ãã ç¹å¥å®é¡çµ¦ä»éã®å¤ãã¯è²¯éï¼é éï¼ã«åã£ã¦ãã¾ã£ãããã§ã¯å®æ½ãããç¹å¥å®é¡çµ¦ä»éã¯å¹æãã£ãã®ã§ããããï¼ å¹æãçå符ããããã¾ããã ç¹å¥å®é¡çµ¦ä»éã®å¤ãã¯ãã®ã¾ã¾ä½¿ããã¦ããªãã¨ãããã¼ã¿ããããã§ã
æ´»åä¼æ¢ä¸ã®ï¼äººçµã¦ããããï½ï½ï½ï½ï½ï½ï½ï½ãGTãã®ï½ï½ï½ï½ï½ï½ ãï¼æ¥ãèªèº«ã®ã¤ã³ã¹ã¿ã°ã©ã ãæ´æ°ãå£å ããé¦ã«ããã¦èãçã£èµ¤ã«ãªã£ãé¡ãå ¬éããæ²»çæ³ãªã©ã®ã¢ããã¤ã¹ãæ±ããã ï½ï½ï½ï½ï½ï½ ã¯ãæè¿â¦é¡ã®èã®æ§åãããããâ¦å¤ããå£ã®å¨ãã«ççãèµ·ãã¯ããâ¦ããï¼ã±æãçµã¡ã¾ãããâ¦ä¸åã«æ²»ããªããã¨åç½ããèãçã£èµ¤ã«ãªã£ãåçãã¢ããã ãç®èç§ãï¼ã¤è¡ã£ããã©â¦ãããããã«çµéãä¼ãã¦ãå¥ã®å¡ãè¬ãå æè¬ãå¦æ¹ãã¦ããã£ãããããã©â¦ãä¸æçè¯ããªãäºãããã°ãã¾ãã¶ãè¿ãã¦ãç¹°ãè¿ãâ¦ãã¨ãªããªãçç¶ãè¯ããªããªãã¨ããããéå»è©¦ããå¡ãè¬ã¯ããã³ã¤ããã³ã¬ã¯ãã ããããããã¯ãå æè¬ã¯ãã»ã¬ã¹ã¿ãã³ããã©ãã¢ãã©ããä¸æçãªãã®ã§ã飲ãã§ã¦ãè¯ããªããã¨ãããã°ãæªåãããã¨ãããâ¦å¹ãã¦ãã®ãï¼è¬ï¼ä»ã¯ãåå³ææ¯æ¹¯ã¨ããæ¼¢æ¹ã¨ãï¼ã¤ã®ãã¿ãã³å¤ã飲ãã§ããâ¦è¯ããªãæ°é ã
ã¯ããã«ã»ãæ¨æ¶ãã®åº¦ç§ãã¡ã¯ã æ代ã®å¤é©æã«ãããç¾å¨ã®å°å¦æ ¡æè²ã®å¨ãæ¹ãéã¿ã ã°ãã¼ãã«ç¤¾ä¼ã«ãããæ代ã®å 端㨠ã¦ããããªæ®ããã®ä¸¡ç«ãå³ãããã®å¦ã³ã®å ´ ããªã«ã¿ããã£ãã¹ã¯ã¼ã«ããåµãã¾ãã ãæ ¡é·ãã¿å çã®èªå·±ç´¹ä»ã ç岡åºèº«ãç¾å¨ã¯ç¥å¥å·å¨ä½ã ï¼äººã®åã©ãã¨ï¼äººæ®ããã ï¼æã¾ã§ã¯å¾ªç°å¨ç æ£ã§ã®çè·å¸«ã¨ãã¦å¤åã éè·å¾ã¯ããªã¼ã©ã³ã¹ã®çè·å¸«ã¨ ã¹ã¯ã¼ã«ã®æ ¡é·ã¨ãã¦æ°è¦äºæ¥ã®æºåã«å¥èµ°ããæ¯æ¥ã§ãã 第äºåã®é·ç·åºç£å¾ã第ä¸åã®æã¨ã¯éãã å ¨ã¦ã«ããã¦æãããåè²ã¦ã«æ©ãã ç¹ã«ãã£ã¨ã®æãã§éå§ããé¢ä¹³é£ã¯ã æä½ãã®ãã®ã§ã¢ããã£ã©ãã·ã¼ãèµ·ããã ãã«ãã¢ã¬ã«ã®ã¼ãçºè¦ããã å£ã«ãããã®ããç±³ã»ç¹å®ã®éèã»èã»å¡©ã¨å¤æãã ããããããã«é£ã«ã¯æ°ãé ãã ç¥çµè³ªã«ãªãã¤ã¤ãå¦ã³ãå®è·µãã¦ãããã¡ã« ããã¥ã©ãªã¹ãã¨ãªãã ã²ãããªãã¨ããSNS㧠ãã®ã¹ã¯ã¼
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}